Research innovations from CPC investigators
Members of the Cancer Prevention and Control research program at IU Simon Comprehensive Cancer Center are leading remarkable laboratory and clinical studies that reduce the burden of cancer.
Guiding drug therapy using patient genetics
CPC members Tyler Shugg, PhD, Zeruesenay Desta, PhD, Bryan Schneider, MD, and Todd Skaar, PhD, are making an impact along with other colleagues from Indiana University School of Medicine.
Their study using patient genetics to guide drug therapy and manage drug interactions that could potentially benefit patients with advanced cancer was recently published in the renowned journal JCO Precision Oncology.
Andrea Hohmann named Distinguished Professor
Andrea Hohmann, PhD, was one of six IU faculty members named as Distinguished Professors in 2026. This is the most prestigious appointment offered to honor faculty whose outstanding scholarship, artistic or literary distinction, or other achievements have won significant recognition by peers. Along with her pioneering work on the cannabinoid and endocannabinoid mechanisms advancing non-opioid, non-addictive strategies for pain relief, Hohmann is recognized globally for her scientific excellence, and her contributions have been transformative to neuroscience and public health.
Dr. Travis answers questions about study on testicular cancer survivors’ long-term health effects
In a study of nearly 800 testicular cancer survivors, researchers identified long-term health effects of chemotherapy used to treat testicular cancer, including differences in renal function, cardiovascular risk, and chronic health conditions. Lois B. Travis, MD, and colleagues at IU and elsewhere will use their findings to inform national follow-up guidelines for cisplatin-treated testicular cancer survivors in the future.
